Look for:

Our offer for

AB SCIENCE S.A.


ISIN:
FR0010557264
WKN:
-

2022/01/26 14:48:54
Price
9.755 EUR
Difference 1.93% (0.19)

General attributes

ISINFR0010557264
SymbolAB
ExchangeEuronext Paris
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)448 EUR
BenchmarkCAC 40 INDEX

Market data

Bid (Bid size)9.75 EUR (464)
Ask (Ask size)9.79 EUR (755)
Open9.50 EUR
High9.86 EUR
Low9.50 EUR
Close (prev. day)9.57 EUR
VWAP9.697612 EUR
Volume (pcs)29,423
Trading volume285,333.00
Number of trades183
Last size126

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Annual report: AB SCIENCE S.A.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2022/01/26 14:48:54
Price
9.755 EUR
Difference 1.93% (0.19)

General attributes

ISINFR0010557264
SymbolAB
ExchangeEuronext Paris
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)448 EUR
BenchmarkCAC 40 INDEX

Market data

Bid (Bid size)9.75 EUR (464)
Ask (Ask size)9.79 EUR (755)
Open9.50 EUR
High9.86 EUR
Low9.50 EUR
Close (prev. day)9.57 EUR
VWAP9.697612 EUR
Volume (pcs)29,423
Trading volume285,333.00
Number of trades183
Last size126

Performance and Risk

6M1Y3Y
Perf (%)-37.49%-40.85%+140.45%
Perf (abs.)-5.74-6.61+5.59
Beta0.460.240.48
Volatility45.1971.2768.36
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)10.283 EUR (81,534)
Ø price 30 days | Ø volume 30 days (pcs.)11.668 EUR (55,423)
Ø price 100 days | Ø volume 100 days (pcs.)12.493 EUR (64,838)
Ø price 250 days | Ø volume 250 days (pcs.)13.232 EUR (175,946)
YTD High | date13.340 EUR (2022/01/04)
YTD Low | date9.510 EUR (2022/01/25)
52 Weeks High | date17.940 EUR (2021/02/04)
52 Weeks Low | date6.950 EUR (2021/06/10)

All listings for AB SCIENCE S.A.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2022/01/2522:269.67 EUR0.001
Stuttgart2022/01/2615:139.74 EUR0.008
Munich2022/01/2608:059.745 EUR0.001
London Stock Exchange2021/01/2610:2016.5193 EUR0.002
Frankfurt2022/01/2608:019.60 EUR0.001
FINRA other OTC Issues2022/01/1916:3312.20 USD0.001
Euronext Paris2022/01/2614:489.755 EUR0.29183
Duesseldorf2022/01/2614:579.745 EUR0.009
Berlin2022/01/2608:059.605 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=137388&ID_TYPE_IMAGE_LOGO=2

Contact Details

AB SCIENCE SA
- -
3, Avenue George V - 75008 Paris
Telefon: 33-1-47-20-00-14
Fax: 33-1-47-20-24-11
E-mail: contact@ab-science.com

PDF Downloads

Annual report: AB SCIENCE S.A.PDF Download

Company Profile

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. It develops pharmaceutical products for the treatment of cancer, neurological, and inflammatory diseases. The firm's pipeline includes Masitinib and AB8939. The company was founded by Alain Moussy and Jean-Pierre Kinet on July 11, 2001 and is headquartered in Paris, France.


Board of directors

Jean-Pierre KinetMember of Supervisory Board
Béatrice BihrMember of Supervisory Board
Emmanuelle Mourey-PelaezMember of Supervisory Board
Nathalie Riez ThiolletMember of Supervisory Board
Patrick MoussyMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.